Sonrotoclax Clinical Trials (2026): 24 Studies for Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
24 Sonrotoclax clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma) and 4,506 total planned enrollment. 5 Phase 3 Sonrotoclax trials and 11 Phase 2 are listed. 17 Sonrotoclax clinical trials are actively recruiting at 112 U.S. sites across 33 states. Most recent activity: NCT06854003 (Nov 2039).
Where to Participate: All Sonrotoclax Trial Sites in the U.S. (112 sites across 33 states)
Every actively recruiting Sonrotoclaxtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama At Birmingham Hospital | Birmingham35294-0004 | NCT04973605 | Map |
| AL | University of Alabama At Birmingham Hospital | Birmingham35294-0004 | NCT06742996 | Map |
| AZ | Mayo Clinic Phoenix | Phoenix85054-4502 | NCT06634589 | Map |
| AZ | University of Arizona Cancer Center | Tucson85724-0001 | NCT06742996 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06859008 | Map |
| CA | City of Hope National Medical Center | Duarte91010-3012 | NCT04973605 | Map |
| CA | Ucsf Fresno | Fresno93701 | NCT06742996 | Map |
| CA | City of Hope Irvine Lennar | Irvine92618-2377 | NCT04973605 | Map |
| CA | Kaiser Permanente Southern California | Irvine92618-3734 | NCT06742996 | Map |
| CA | Uci Health Laguna Hills | Laguna Hills92653 | NCT06943872 | Map |
| CA | University of Southern California Norris Comprehensive | Los Angeles90033 | NCT06634589 | Map |
| CA | Chao Family Comprehensive Cancer Center | Orange92868-3201 | NCT06943872 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304-2205 | NCT06943872 | Map |
| CA | Scripps Prebys Cancer Center | San Diego92103-2106 | NCT06943872 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) Usor | Aurora80012-5405 | NCT06943872 | Map |
| CT | Yale University Yale Cancer Center | New Haven06520-8028 | NCT06742996 | Map |
| CT | Yale University Yale Cancer Center | New Haven06520-8028 | NCT06943872 | Map |
| CT | Eastern Connecticut Hematology and Oncology | Norwich06360-2700 | NCT06943872 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224-1865 | NCT06634589 | Map |
| FL | University of Miami | Miami33136-2107 | NCT04973605 | Map |
| FL | Memorial Cancer Institute, Memorial Healthcare System | Pembroke Pines33026-4119 | NCT06742996 | Map |
| FL | Moffitt Cancer Center | Tampa33612-9496 | NCT06634589 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06742996 | Map |
| FL | Cleveland Clinic Florida | Weston33331-3609 | NCT06943872 | Map |
| GA | Emory University Winship Cancer Center | Atlanta30322-1013 | NCT04973605 | Map |
| IL | Northwestern University | Chicago60611 | NCT06943872 | Map |
| IL | Rush University Medical Center | Chicago60612 | NCT06742996 | Map |
| IL | University of Chicago Medical Center | Chicago60637-1443 | NCT04973605 | Map |
| IL | Illinois Cancer Specialists (Niles) Usor | Niles60714-5905 | NCT06943872 | Map |
| IN | Fort Wayne Medical Oncology and Hematology | Fort Wayne46804 | NCT06742996 | Map |
| IA | Mission Cancer and Blood | Waukee50263 | NCT06742996 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205-2003 | NCT06634589 | Map |
| KY | University of Louisville, Brown Cancer Center | Louisville40202 | NCT06943872 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809-3738 | NCT06943872 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201-1544 | NCT06742996 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201-1544 | NCT06943872 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06854003 | Map |
| MA | Dana Farber Cancer Institute | Boston02215-5418 | NCT06943872 | Map |
| MA | Dana Farber Cancer Institute Longwood Medical Center | Boston02215-5418 | NCT06742996 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06854003 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06849713 | Map |
| MI | University of Michigan | Ann Arbor48109-1382 | NCT06742996 | Map |
| MI | The Cancer and Hematology Centers | Grand Rapids49503-2563 | NCT06742996 | Map |
| MI | The Cancer and Hematology Centers | Grand Rapids49503-2563 | NCT06943872 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06634589 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06742996 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06943872 | Map |
| MS | Hattiesburg Hematology and Oncology Clinic | Hattiesburg39401-7233 | NCT06742996 | Map |
| MO | Washington University | St Louis63110 | NCT06854003 | Map |
| MO | Washington University School of Medicine | St Louis63110-1010 | NCT04973605 | Map |
| MO | Washington University School of Medicine | St Louis63110-1010 | NCT06634589 | Map |
| MO | Washington University School of Medicine | St Louis63110-1010 | NCT06742996 | Map |
| NE | Nebraska Cancer Specialists St Francis Grand Island | Grand Island68803 | NCT06742996 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130-2042 | NCT06742996 | Map |
| NJ | Summit Medical Group | Florham Park07932-1049 | NCT06634589 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601-1915 | NCT04973605 | Map |
| NJ | The Valley Hospital, Inc | Paramus07652 | NCT06742996 | Map |
| NJ | Sidney Kimmel Comprehensive Cancer Center Washington Twp | Sewell08080 | NCT06943872 | Map |
| NM | Christus St Vincent Regional Cancer Center | Santa Fe87505 | NCT06943872 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT06634589 | Map |
| NY | Icahn School of Medicine At Mount Sinai | New York10029-6504 | NCT06634589 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06854003 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT04973605 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06634589 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06943872 | Map |
| NY | Weill Cornell Medical College Newyork Presbyterian Hospital | New York10065-4870 | NCT04973605 | Map |
| NY | Weill Cornell Medical College Newyork Presbyterian Hospital | New York10065-4870 | NCT06634589 | Map |
| NY | University of Rochester | Rochester14642-0001 | NCT06634589 | Map |
| NY | Clinical Research Alliance, Inc | Westbury11590-5119 | NCT06943872 | Map |
| NC | University of North Carolina At Chapel Hill | Chapel Hill27514-4220 | NCT06943872 | Map |
| NC | Atrium Health Levine Cancer Institute (Lci) | Charlotte28204-2990 | NCT06742996 | Map |
| NC | Levine Cancer Center | Charlotte28204-2990 | NCT06943872 | Map |
| NC | Duke University | Durham27710 | NCT06742996 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06742996 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06943872 | Map |
| OH | Oncology Hematology Care Clinical Trials, Llc | Cincinnati45245-1995 | NCT06943872 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195-0001 | NCT06742996 | Map |
| OH | University Hospitals | Cleveland44106-1716 | NCT06742996 | Map |
| OH | Ohio Health Research Institute | Columbus43214-3907 | NCT06742996 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210-1280 | NCT06742996 | Map |
| OH | The James Cancer Hospital and Solove Research Institute At Ohio State University | Columbus43210-1240 | NCT04973605 | Map |
| OR | Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene97401 | NCT06943872 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033 | NCT06742996 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033 | NCT06943872 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111-2434 | NCT06634589 | Map |
| PA | Thomas Jefferson University | Philadelphia19107-4216 | NCT06943872 | Map |
| PA | Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh15232-1309 | NCT06943872 | Map |
| PA | McGlinn Cancer Institute | West Reading19611-2143 | NCT06742996 | Map |
| TN | Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga | Chattanooga37404 | NCT06943872 | Map |
| TN | Tennessee Oncology | Nashville37205 | NCT06742996 | Map |
| TN | Tennessee Oncology | Nashville37205 | NCT06943872 | Map |
| TN | Tennessee Oncology Nashville St Thomas Midtown Clinic | Nashville37205 | NCT06742996 | Map |
| TX | Texas Oncology Baylorcharles A Sammons Cancer Center | Dallas75246-2003 | NCT06943872 | Map |
| TX | Md Anderson Cancer Center | Houston77030-3907 | NCT06742996 | Map |
| TX | The University of Texas Md Anderson Cancer Center | Houston77030-4009 | NCT06634589 | Map |
| TX | Texas Oncology Austin Midtown | Round Rock78681-4019 | NCT06742996 | Map |
| TX | Texas Oncology San Antonio Medical Center Usor | San Antonio78240-5251 | NCT06943872 | Map |
| TX | Texas Oncology Tyler | Tyler75702-7522 | NCT06943872 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112-5550 | NCT04973605 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112-5550 | NCT06634589 | Map |
| VA | University of Virginia | Charlottesville22908-0817 | NCT06742996 | Map |
| VA | Virgina Cancer Specialists | Gainesville20155-3257 | NCT06742996 | Map |
| VA | Vcu Massey Cancer Center | Richmond23298-5026 | NCT06742996 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06839053 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109-4433 | NCT07277231 | Map |
| WA | University of Washington | Seattle98195 | NCT04973605 | Map |
| WA | Northwest Cancer Specialist, Pc(Us Oncology Research) | Vancouver98684-6930 | NCT06742996 | Map |
| WA | Northwest Cancer Specialist, Pc(Us Oncology Research) | Vancouver98684-6930 | NCT06943872 | Map |
| WI | University of Wisconsin | Madison53792-0001 | NCT06634589 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792-0001 | NCT04973605 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226-1222 | NCT04973605 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226-1222 | NCT06634589 | Map |
Sonrotoclax clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | 1 | 5 |
| P1/P2 | 3 | 3 | |||
| P2 | 6 | 3 | 2 | 11 | |
| P3 | 3 | 1 | 1 | 5 |
Recruiting Sonrotoclax clinical trials (17)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06854003 | BRAZANBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 60 | Apr 2025 |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | P3 | Chronic Lymphocytic Leukemia | 466 | Jan 2026 |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | P1/P2 | Chronic Lymphocytic Leukemia | 258 | Jan 2025 |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | P2 | Chronic Lymphocytic Leukemia | 30 | Jun 2025 |
| NCT06742996 | CELESTIAL-RRMCLA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | P3 | Mantle Cell Lymphoma | 300 | Mar 2025 |
| NCT06943872 | CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | Chronic Lymphocytic Leukemia | 630 | Jun 2025 |
| NCT07277231 | BGB-11417A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | P3 | Chronic Lymphocytic Leukemia | 500 | Jan 2026 |
| NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | P2 | Mantle Cell Lymphoma | 40 | Jun 2026 |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | P2 | Chronic Lymphocytic Leukemia | 66 | May 2024 |
| NCT06849713 | BOSonZanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL | P2 | Chronic Lymphocytic Leukemia | 40 | May 2025 |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | P1/P2 | B-cell Malignancy | 80 | Nov 2024 |
| NCT07548255 | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL | P1 | Intermediate-to-High-Risk Mantle Cell Lymphoma | 28 | Apr 2026 |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | P2 | AL Amyloidosis (AL) | 39 | Jan 2026 |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 37 | Aug 2025 |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | P2 | Acute Myeloid Leukemia | 205 | May 2026 |
| NCT04973605 | BGB-11417A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | P1/P2 | Relapsed/Refractory Multiple Myeloma | 246 | Sep 2021 |
| NCT04271956 | CLL-RT1Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation | P2 | Richter Transformation | 83 | Feb 2020 |
Sonrotoclax clinical trials by indication
Chronic Lymphocytic Leukemia (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07321652 | — | P3 | not yet recruiting | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL |
| NCT06697184 | — | P1/P2 | recruiting | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. |
| NCT06839053 | — | P2 | recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma |
| NCT06943872 | CELESTIAL-RRCLL | P3 | recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
| NCT07277231 | BGB-11417 | P3 | recruiting | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia |
| NCT06367374 | — | P2 | not yet recruiting | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL |
| NCT06849713 | BOSon | P2 | recruiting | Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL |
| NCT06637501 | — | P2 | active not recruiting | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia |
Mantle Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06854003 | BRAZAN | P2 | recruiting | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma |
| NCT06742996 | CELESTIAL-RRMCL | P3 | recruiting | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) |
| NCT07341191 | — | P2 | recruiting | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy |
Acute Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07548710 | — | P2 | recruiting | Study of SA+X in the Treatment of Newly Diagnosed AML |
| NCT06497062 | — | P2 | active not recruiting | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia |
Intermediate-to-High-Risk Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07548255 | — | P1 | not yet recruiting | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL |
AL Amyloidosis (AL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07335887 | — | P2 | not yet recruiting | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07141511 | BG-71332 | P1 | completed | A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06859008 | — | P1 | recruiting | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
B-cell Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06634589 | — | P1/P2 | recruiting | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies |
Not Determined (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06543043 | BGB-11417 | P1 | completed | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers |
CLL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06073821 | BGB-11417 | P3 | active not recruiting | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) |
Waldenstrom Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05952037 | — | P2 | active not recruiting | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia |
Relapsed/Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04973605 | BGB-11417 | P1/P2 | recruiting | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma |
Mature B-Cell Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04277637 | BGB-11417 | P1 | active not recruiting | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies |
Richter Transformation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04271956 | CLL-RT1 | P2 | recruiting | Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation |
Sonrotoclax pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BGB-11417 | NCT06073821 | P3 | active not recruiting | CLL | 652 | — |
| CELESTIAL-RRMCL | NCT06742996 | P3 | recruiting | Mantle Cell Lymphoma | 300 | — |
| CELESTIAL-RRCLL | NCT06943872 | P3 | recruiting | Chronic Lymphocytic Leukemia | 630 | — |
| BGB-11417 | NCT07277231 | P3 | recruiting | Chronic Lymphocytic Leukemia | 500 | — |
| BRAZAN | NCT06854003 | P2 | recruiting | Mantle Cell Lymphoma | 60 | — |
| BOSon | NCT06849713 | P2 | recruiting | Chronic Lymphocytic Leukemia | 40 | — |
| CLL-RT1 | NCT04271956 | P2 | recruiting | Richter Transformation | 83 | PMID 38071379 |
All Sonrotoclax trials (24)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06854003 | BRAZAN | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | P2 | recruiting | 60 | Christine Ryan | Apr 2025 |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | P3 | not yet recruiting | 466 | Alliance for Clinical Trials in Oncology | Jan 2026 | |
| NCT06073821 | BGB-11417 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | P3 | active not recruiting | 652 | BeOne Medicines | Nov 2023 |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | P1/P2 | recruiting | 258 | BeOne Medicines | Jan 2025 | |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | P2 | recruiting | 30 | Fred Hutchinson Cancer Center | Jun 2025 | |
| NCT06742996 | CELESTIAL-RRMCL | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | P3 | recruiting | 300 | BeOne Medicines | Mar 2025 |
| NCT06943872 | CELESTIAL-RRCLL | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | P3 | recruiting | 630 | BeOne Medicines | Jun 2025 |
| NCT07277231 | BGB-11417 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | P3 | recruiting | 500 | BeOne Medicines | Jan 2026 |
| NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | P2 | recruiting | 40 | Canadian Cancer Trials Group | Jun 2026 | |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | P2 | not yet recruiting | 66 | Institute of Hematology & Blood Diseases Hospital, China | May 2024 | |
| NCT06849713 | BOSon | Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL | P2 | recruiting | 40 | Massachusetts General Hospital | May 2025 |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | P1/P2 | recruiting | 80 | BeOne Medicines | Nov 2024 | |
| NCT06637501 | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | P2 | active not recruiting | 94 | BeOne Medicines | Nov 2024 | |
| NCT07548255 | The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL | P1 | not yet recruiting | 28 | Ruijin Hospital | Apr 2026 | |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | P2 | not yet recruiting | 39 | Peking University People's Hospital | Jan 2026 | |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | recruiting | 37 | City of Hope Medical Center | Aug 2025 | |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | P2 | recruiting | 205 | Ruijin Hospital | May 2026 | |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | P2 | active not recruiting | 114 | BeOne Medicines | Oct 2023 | |
| NCT06497062 | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | P2 | active not recruiting | 47 | Shanghai Jiao Tong University School of Medicine | Oct 2024 | |
| NCT04277637 | BGB-11417 | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | P1 | active not recruiting | 437 | BeOne Medicines | Mar 2020 |
| NCT04973605 | BGB-11417 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | P1/P2 | recruiting | 246 | BeOne Medicines | Sep 2021 |
| NCT04271956 | CLL-RT1 | Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation | P2 | recruiting | 83 | German CLL Study Group | Feb 2020 |
| NCT07141511 | BG-71332 | A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults | P1 | completed | 24 | BeOne Medicines | Sep 2025 |
| NCT06543043 | BGB-11417 | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers | P1 | completed | 30 | BeiGene | Aug 2024 |
Sonrotoclax clinical trials: frequently asked questions
- How many Sonrotoclax clinical trials are there?
- 24 Sonrotoclax clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 13 are actively recruiting participants. 2 are marked completed.
- Are Sonrotoclax clinical trials recruiting in 2026?
- Yes — 13 Sonrotoclax trials are actively recruiting in 2026, with 112 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Sonrotoclax being studied for?
- Sonrotoclax is being studied for Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Acute Myeloid Leukemia, Refractory Mantle Cell Lymphoma and 43 more. The trials are grouped by indication on this page.
- What phase is Sonrotoclax in?
- Sonrotoclax clinical trials span 5 Phase 3, 11 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Sonrotoclax clinical trials?
- The lead sponsor across the most Sonrotoclax trials is BeOne Medicines, with 12 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Sonrotoclaxas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: